The role of Nrf2 signaling in counteracting neurodegenerative diseases

FEBS Journal

Volumn 285, Issue 19, 2018, Pages 3576-3590

  Dinkova Kostova, Albena T ^a,b   Kostov, Rumen V ^a   Kazantsev, Aleksey G ^c,d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Effective Therapeutics   (United States)

Author keywords

neurodegeneration; neuroinflammation; neuroprotection; Nrf2 activator; oxidative stress

Indexed keywords

TRANSCRIPTION FACTOR NRF2;

AGING; AUTOPHAGY; CELL FUNCTION; CELL PROTECTION; DEGENERATIVE DISEASE; DISEASE COURSE; HUMAN; MITOCHONDRION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SYMPTOM; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 85041101298     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.14379     Document Type: Review

References (113)

1. Hayes JD & Dinkova-Kostova AT (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39, 199–218.
2. Zhang DD, Lo SC, Cross JV, Templeton DJ & Hannink M (2004) Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24, 10941–10953.
3. Cullinan SB, Gordan JD, Jin J, Harper JW & Diehl JA (2004) The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 24, 8477–8486.
4. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K & Yamamoto M (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24, 7130–7139.
5. Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD & Cuadrado A (2011) SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol 31, 1121–1133.
6. Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A & Hayes JD (2013) Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32, 3765–3781.
7. Wu T, Zhao F, Gao B, Tan C, Yagishita N, Nakajima T, Wong PK, Chapman E, Fang D & Zhang DD (2014) Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis. Genes Dev 28, 708–722.
8. Lo JY, Spatola BN & Curran SP (2017) WDR23 regulates NRF2 independently of KEAP1. PLoS Genet 13, e1006762.
9. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M & Kensler TW (2003) Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 278, 8135–8145.
10. Pajares M, Jimenez-Moreno N, Garcia-Yague AJ, Escoll M, de Ceballos ML, Van Leuven F, Rabano A, Yamamoto M, Rojo AI & Cuadrado A (2016) Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. Autophagy 12, 1902–1916.
11. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI et al. (2010) The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 12, 213–223.
12. Wild AC, Moinova HR & Mulcahy RT (1999) Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. J Biol Chem 274, 33627–33636.
13. Moinova HR & Mulcahy RT (1999) Up-regulation of the human gamma-glutamylcysteine synthetase regulatory subunit gene involves binding of Nrf-2 to an electrophile responsive element. Biochem Biophys Res Commun 261, 661–668.
14. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M & Biswal S (2002) Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62, 5196–5203.
15. Lee JM, Calkins MJ, Chan K, Kan YW & Johnson JA (2003) Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 278, 12029–12038.
16. Wu KC, Cui JY & Klaassen CD (2011) Beneficial role of Nrf2 in regulating NADPH generation and consumption. Toxicol Sci 123, 590–600.
17. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M & Motohashi H (2012) Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22, 66–79.
18. Holmstrom KM, Baird L, Zhang Y, Hargreaves I, Chalasani A, Land JM, Stanyer L, Yamamoto M, Dinkova-Kostova AT & Abramov AY (2013) Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration. Biol Open 2, 761–770.
19. Dinkova-Kostova AT & Abramov AY (2015) The emerging role of Nrf2 in mitochondrial function. Free Radic Biol Med 88, 179–188.
20. East DA, Fagiani F, Crosby J, Georgakopoulos ND, Bertrand H, Schaap M, Fowkes A, Wells G & Campanella M (2014) PMI: a DeltaPsi independent pharmacological regulator of mitophagy. Chem Biol 21, 1585–1596.
21. Georgakopoulos ND, Frison M, Alvarez MS, Bertrand H, Wells G & Campanella M (2017) Reversible Keap1 inhibitors are preferential pharmacological tools to modulate cellular mitophagy. Sci Rep 7, 10303.
22. Knatko EV, Ibbotson SH, Zhang Y, Higgins M, Fahey JW, Talalay P, Dawe RS, Ferguson J, Huang JT, Clarke R et al. (2015) Nrf2 activation protects against solar-simulated ultraviolet radiation in mice and humans. Cancer Prev Res (Phila) 8, 475–486.
23. Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Hayashi M, Sekine H, Tanaka N, Moriguchi T, Motohashi H, Nakayama K et al. (2016) Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun 7, 11624.
24. Johnson DA & Johnson JA (2015) Nrf2–a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med 88, 253–267.
25. Yamazaki H, Tanji K, Wakabayashi K, Matsuura S & Itoh K (2015) Role of the Keap1/Nrf2 pathway in neurodegenerative diseases. Pathol Int 65, 210–219.
26. Kumar H, Lim HW, More SV, Kim BW, Koppula S, Kim IS & Choi DK (2012) The role of free radicals in the aging brain and Parkinson's Disease: convergence and parallelism. Int J Mol Sci 13, 10478–10504.
27. Wang Q, Li WX, Dai SX, Guo YC, Han FF, Zheng JJ, Li GH & Huang JF (2017) Meta-analysis of Parkinson's disease and Alzheimer's disease revealed commonly impaired pathways and dysregulation of NRF2-dependent genes. J Alzheimers Dis 56, 1525–1539.
28. Mota SI, Costa RO, Ferreira IL, Santana I, Caldeira GL, Padovano C, Fonseca AC, Baldeiras I, Cunha C, Letra L et al. (2015) Oxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer's disease. Biochim Biophys Acta 1852, 1428–1441.
29. Rojo AI, Pajares M, Rada P, Nunez A, Nevado-Holgado AJ, Killik R, Van Leuven F, Ribe E, Lovestone S, Yamamoto M et al. (2017) NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology. Redox Biol 13, 444–451.
30. Prasad KN (2016) Simultaneous activation of Nrf2 and elevation of antioxidant compounds for reducing oxidative stress and chronic inflammation in human Alzheimer's disease. Mech Ageing Dev 153, 41–47.
31. Lipton SA, Rezaie T, Nutter A, Lopez KM, Parker J, Kosaka K, Satoh T, McKercher SR, Masliah E & Nakanishi N (2016) Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models. Cell Death Dis 7, e2499.
32. Kwon SH, Ma SX, Hwang JY, Lee SY & Jang CG (2015) Involvement of the Nrf2/HO-1 signaling pathway in sulfuretin-induced protection against amyloid beta25-35 neurotoxicity. Neuroscience 304, 14–28.
33. Williamson TP, Johnson DA & Johnson JA (2012) Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity. Neurotoxicology 33, 272–279.
34. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW & Johnson JA (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc Natl Acad Sci USA 106, 2933–2938.
35. Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML, Yamamoto M & Cuadrado A (2010) Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58, 588–598.
36. Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernandez-Ruiz J & Cuadrado A (2011) Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal 14, 2347–2360.
37. Alarcon-Aguilar A, Luna-Lopez A, Ventura-Gallegos JL, Lazzarini R, Galvan-Arzate S, Gonzalez-Puertos VY, Moran J, Santamaria A & Konigsberg M (2014) Primary cultured astrocytes from old rats are capable to activate the Nrf2 response against MPP+ toxicity after tBHQ pretreatment. Neurobiol Aging 35, 1901–1912.
38. Jimenez-Sanchez M, Licitra F, Underwood BR & Rubinsztein DC (2017) Huntington's disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med 7, a024240.
39. Prasad KN & Bondy SC (2016) Inhibition of early biochemical defects in prodromal Huntington's disease by simultaneous activation of Nrf2 and elevation of multiple micronutrients. Curr Aging Sci 9, 61–70.
40. Esteras N, Dinkova-Kostova AT & Abramov AY (2016) Nrf2 activation in the treatment of neurodegenerative diseases: a focus on its role in mitochondrial bioenergetics and function. Biol Chem 397, 383–400.
41. Ludtmann MH, Angelova PR, Zhang Y, Abramov AY & Dinkova-Kostova AT (2014) Nrf2 affects the efficiency of mitochondrial fatty acid oxidation. Biochem J 457, 415–424.
42. Greco T & Fiskum G (2010) Brain mitochondria from rats treated with sulforaphane are resistant to redox-regulated permeability transition. J Bioenerg Biomembr 42, 491–497.
43. Greco T, Shafer J & Fiskum G (2011) Sulforaphane inhibits mitochondrial permeability transition and oxidative stress. Free Radic Biol Med 51, 2164–2171.
44. Piantadosi CA, Carraway MS, Babiker A & Suliman HB (2008) Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. Circ Res 103, 1232–1240.
45. Sabouny R, Fraunberger E, Geoffrion M, Ng AC, Baird SD, Screaton RA, Milne R, McBride HM & Shutt TE (2017) The Keap1-Nrf2 stress response pathway promotes mitochondrial hyperfusion through degradation of the mitochondrial fission protein Drp1. Antioxid Redox Signal 27, 1447–1459.
46. Kandimalla R, Manczak M, Fry D, Suneetha Y, Sesaki H & Reddy PH (2016) Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease. Hum Mol Genet 25, 4881–4897.
47. Navarro E, Gonzalez-Lafuente L, Perez-Liebana I, Buendia I, Lopez-Bernardo E, Sanchez-Ramos C, Prieto I, Cuadrado A, Satrustegui J, Cadenas S et al. (2017) Heme-oxygenase I and PCG-1alpha regulate mitochondrial biogenesis via microglial activation of alpha7 nicotinic acetylcholine receptors using PNU282987. Antioxid Redox Signal 27, 93–105.
48. Tufi R, Gandhi S, de Castro IP, Lehmann S, Angelova PR, Dinsdale D, Deas E, Plun-Favreau H, Nicotera P, Abramov AY et al. (2014) Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease. Nat Cell Biol 16, 157–166.
49. Dinkova-Kostova AT, Baird L, Holmstrom KM, Meyer CJ & Abramov AY (2015) The spatiotemporal regulation of the Keap1-Nrf2 pathway and its importance in cellular bioenergetics. Biochem Soc Trans 43, 602–610.
50. Paupe V, Dassa EP, Goncalves S, Auchere F, Lonn M, Holmgren A & Rustin P (2009) Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One 4, e4253.
51. Shan Y, Schoenfeld RA, Hayashi G, Napoli E, Akiyama T, Iodi Carstens M, Carstens EE, Pook MA & Cortopassi GA (2013) Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich's ataxia YG8R mouse model. Antioxid Redox Signal 19, 1481–1493.
52. D'Oria V, Petrini S, Travaglini L, Priori C, Piermarini E, Petrillo S, Carletti B, Bertini E & Piemonte F (2013) Frataxin deficiency leads to reduced expression and impaired translocation of NF-E2-related factor (Nrf2) in cultured motor neurons. Int J Mol Sci 14, 7853–7865.
53. Abeti R, Uzun E, Renganathan I, Honda T, Pook MA & Giunti P (2015) Targeting lipid peroxidation and mitochondrial imbalance in Friedreich's ataxia. Pharmacol Res 99, 344–350.
54. Sahdeo S, Scott BD, McMackin MZ, Jasoliya M, Brown B, Wulff H, Perlman SL, Pook MA & Cortopassi GA (2014) Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia. Hum Mol Genet 23, 6848–6862.
55. Jarrott B & Williams SJ (2016) Chronic brain inflammation: the neurochemical basis for drugs to reduce inflammation. Neurochem Res 41, 523–533.
56. Hoenen C, Gustin A, Birck C, Kirchmeyer M, Beaume N, Felten P, Grandbarbe L, Heuschling P & Heurtaux T (2016) Alpha-synuclein proteins promote pro-inflammatory cascades in microglia: stronger effects of the A53T mutant. PLoS One 11, e0162717.
57. Quinti L, Dayalan Naidu S, Trager U, Chen X, Kegel-Gleason K, Lleres D, Connolly C, Chopra V, Low C, Moniot S et al. (2017) KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. Proc Natl Acad Sci USA 114, E4676–E4685.
58. Townsend BE & Johnson RW (2016) Sulforaphane induces Nrf2 target genes and attenuates inflammatory gene expression in microglia from brain of young adult and aged mice. Exp Gerontol 73, 42–48.
59. Quinti L, Casale M, Moniot S, Pais TF, Van Kanegan MJ, Kaltenbach LS, Pallos J, Lim RG, Naidu SD, Runne H et al. (2016) SIRT2- and NRF2-targeting thiazole-containing compound with therapeutic activity in Huntington's disease models. Cell Chem Biol 23, 849–861.
60. Dinkova-Kostova AT, Jenkins SN, Fahey JW, Ye L, Wehage SL, Liby KT, Stephenson KK, Wade KL & Talalay P (2006) Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. Cancer Lett 240, 243–252.
61. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW et al. (2005) Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 102, 4584–4589.
62. Liu H, Dinkova-Kostova AT & Talalay P (2008) Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles. Proc Natl Acad Sci USA 105, 15926–15931.
63. Fragoulis A, Siegl S, Fendt M, Jansen S, Soppa U, Brandenburg LO, Pufe T, Weis J & Wruck CJ (2017) Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease. Redox Biol 12, 843–853.
64. Serini S & Calviello G (2016) Reduction of oxidative/nitrosative stress in brain and its involvement in the neuroprotective effect of n-3 PUFA in Alzheimer's disease. Curr Alzheimer Res 13, 123–134.
65. Vargas MR, Pehar M, Cassina P, Beckman JS & Barbeito L (2006) Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR-dependent motor neuron apoptosis. J Neurochem 97, 687–696.
66. Neymotin A, Calingasan NY, Wille E, Naseri N, Petri S, Damiano M, Liby KT, Risingsong R, Sporn M, Beal MF et al. (2011) Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med 51, 88–96.
67. Giordano S, Darley-Usmar V & Zhang J (2014) Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol 2, 82–90.
68. Hensley K & Harris-White ME (2015) Redox regulation of autophagy in healthy brain and neurodegeneration. Neurobiol Dis 84, 50–59.
69. Dayalan Naidu S, Dikovskaya D, Gaurilcikaite E, Knatko EV, Healy ZR, Mohan H, Koh G, Laurell A, Ball G, Olagnier D et al. (2017) Transcription factors NRF2 and HSF1 have opposing functions in autophagy. Sci Rep 7, 11023.
70. Olagnier D, Lababidi RR, Hadj SB, Sze A, Liu Y, Naidu SD, Ferrari M, Jiang Y, Chiang C, Beljanski V et al. (2017) Activation of Nrf2 signaling augments vesicular stomatitis virus oncolysis via autophagy-driven suppression of antiviral immunity. Mol Ther 25, 1900–1916.
71. Calap-Quintana P, Soriano S, Llorens JV, Al-Ramahi I, Botas J, Molto MD & Martinez-Sebastian MJ (2015) TORC1 inhibition by rapamycin promotes antioxidant defences in a Drosophila model of Friedreich's ataxia. PLoS One 10, e0132376.
72. Joshi G, Gan KA, Johnson DA & Johnson JA (2015) Increased Alzheimer's disease-like pathology in the APP/PS1DeltaE9 mouse model lacking Nrf2 through modulation of autophagy. Neurobiol Aging 36, 664–679.
73. Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S et al. (2006) Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 67, 1786–1791.
74. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045–2047.
75. Skibinski G, Hwang V, Ando DM, Daub A, Lee AK, Ravisankar A, Modan S, Finucane MM, Shaby BA & Finkbeiner S (2017) Nrf2 mitigates LRRK2- and alpha-synuclein-induced neurodegeneration by modulating proteostasis. Proc Natl Acad Sci USA 114, 1165–1170.
76. Gotzl JK, Lang CM, Haass C & Capell A (2016) Impaired protein degradation in FTLD and related disorders. Ageing Res Rev 32, 122–139.
77. Rainero I, Rubino E, Michelerio A, D'Agata F, Gentile S & Pinessi L (2017) Recent advances in the molecular genetics of frontotemporal lobar degeneration. Funct Neurol 32, 7–16.
78. Luis E, Ortiz A, Eudave L, Ortega-Cubero S, Borroni B, van der Zee J, Gazzina S, Caroppo P, Rubino E, D'Agata F et al. (2016) Neuroimaging correlates of frontotemporal dementia associated with SQSTM1 mutations. J Alzheimers Dis 53, 303–313.
79. Kovacs GG, van der Zee J, Hort J, Kristoferitsch W, Leitha T, Hoftberger R, Strobel T, Van Broeckhoven C & Matej R (2016) Clinicopathological description of two cases with SQSTM1 gene mutation associated with frontotemporal dementia. Neuropathology 36, 27–38.
80. Goode A, Butler K, Long J, Cavey J, Scott D, Shaw B, Sollenberger J, Gell C, Johansen T, Oldham NJ et al. (2016) Defective recognition of LC3B by mutant SQSTM1/p62 implicates impairment of autophagy as a pathogenic mechanism in ALS-FTLD. Autophagy 12, 1094–1104.
81. Kumar V, Islam A, Hassan MI & Ahmad F (2016) Delineating the relationship between amyotrophic lateral sclerosis and frontotemporal dementia: sequence and structure-based predictions. Biochim Biophys Acta 1862, 1742–1754.
82. Yang Y, Tang L, Zhang N, Pan L, Hadano S & Fan D (2015) Six SQSTM1 mutations in a Chinese amyotrophic lateral sclerosis cohort. Amyotroph Lateral Scler Frontotemporal Degener 16, 378–384.
83. Goode A, Rea S, Sultana M, Shaw B, Searle MS & Layfield R (2016) ALS-FTLD associated mutations of SQSTM1 impact on Keap1-Nrf2 signalling. Mol Cell Neurosci 76, 52–58.
84. Bartolome F, Esteras N, Martin-Requero A, Boutoleau-Bretonniere C, Vercelletto M, Gabelle A, Le Ber I, Honda T, Dinkova-Kostova AT, Hardy J et al. (2017) Pathogenic p62/SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates. Sci Rep 7, 1666.
85. Meng J, Lv Z, Qiao X, Li X, Li Y, Zhang Y & Chen C (2017) The decay of redox-stress response capacity is a substantive characteristic of aging: revising the redox theory of aging. Redox Biol 11, 365–374.
86. Kubben N, Zhang W, Wang L, Voss TC, Yang J, Qu J, Liu GH & Misteli T (2016) Repression of the antioxidant NRF2 pathway in premature aging. Cell 165, 1361–1374.
87. Corenblum MJ, Ray S, Remley QW, Long M, Harder B, Zhang DD, Barnes CA & Madhavan L (2016) Reduced Nrf2 expression mediates the decline in neural stem cell function during a critical middle-age period. Aging Cell 15, 725–736.
88. Flowers A, Lee JY, Acosta S, Hudson C, Small B, Sanberg CD & Bickford PC (2015) NT-020 treatment reduces inflammation and augments Nrf-2 and Wnt signaling in aged rats. J Neuroinflammation 12, 174.
89. Acosta S, Jernberg J, Sanberg CD, Sanberg PR, Small BJ, Gemma C & Bickford PC (2010) NT-020, a natural therapeutic approach to optimize spatial memory performance and increase neural progenitor cell proliferation and decrease inflammation in the aged rat. Rejuvenation Res 13, 581–588.
90. Liddell JR (2017) Are astrocytes the predominant cell type for activation of Nrf2 in aging and neurodegeneration? Antioxidants (Basel) 6, 65.
91. Bell KF, Al-Mubarak B, Martel MA, McKay S, Wheelan N, Hasel P, Markus NM, Baxter P, Deighton RF, Serio A et al. (2015) Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2. Nat Commun 6, 7066.
92. Vargas MR & Johnson JA (2009) The Nrf2-ARE cytoprotective pathway in astrocytes. Expert Rev Mol Med 11, e17.
93. Bellaver B, Souza DG, Souza DO & Quincozes-Santos A (2017) Hippocampal astrocyte cultures from adult and aged rats reproduce changes in glial functionality observed in the aging brain. Mol Neurobiol 54, 2969–2985.
94. Baxter PS & Hardingham GE (2016) Adaptive regulation of the brain's antioxidant defences by neurons and astrocytes. Free Radic Biol Med 100, 147–152.
95. Vargas MR, Johnson DA, Sirkis DW, Messing A & Johnson JA (2008) Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 28, 13574–13581.
96. Morrison CD, Pistell PJ, Ingram DK, Johnson WD, Liu Y, Fernandez-Kim SO, White CL, Purpera MN, Uranga RM, Bruce-Keller AJ et al. (2010) High fat diet increases hippocampal oxidative stress and cognitive impairment in aged mice: implications for decreased Nrf2 signaling. J Neurochem 114, 1581–1589.
97. Csiszar A, Gautam T, Sosnowska D, Tarantini S, Banki E, Tucsek Z, Toth P, Losonczy G, Koller A, Reglodi D et al. (2014) Caloric restriction confers persistent anti-oxidative, pro-angiogenic, and anti-inflammatory effects and promotes anti-aging miRNA expression profile in cerebromicrovascular endothelial cells of aged rats. Am J Physiol Heart Circ Physiol 307, H292–H306.
98. Hardie DG, Carling D & Gamblin SJ (2011) AMP-activated protein kinase: also regulated by ADP? Trends Biochem Sci 36, 470–477.
99. Csiszar A, Csiszar A, Pinto JT, Gautam T, Kleusch C, Hoffmann B, Tucsek Z, Toth P, Sonntag WE & Ungvari Z (2015) Resveratrol encapsulated in novel fusogenic liposomes activates Nrf2 and attenuates oxidative stress in cerebromicrovascular endothelial cells from aged rats. J Gerontol A Biol Sci Med Sci 70, 303–313.
100. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218–220.
101. FangFang, Li H, Qin T, Li M & Ma S (2017) Thymol improves high-fat diet-induced cognitive deficits in mice via ameliorating brain insulin resistance and upregulating NRF2/HO-1 pathway. Metab Brain Dis 32, 385–393.
102. Zhang GL, Wang W, Kang YX, Xue Y, Yang H, Zhou CM & Shi GM (2013) Chronic testosterone propionate supplement could activated the Nrf2-ARE pathway in the brain and ameliorated the behaviors of aged rats. Behav Brain Res 252, 388–395.
103. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S et al. (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134, 678–692.
104. Dinkova-Kostova AT, Kostov RV & Canning P (2017) Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants. Arch Biochem Biophys 617, 84–93.
105. Lastres-Becker I, Garcia-Yague AJ, Scannevin RH, Casarejos MJ, Kugler S, Rabano A & Cuadrado A (2016) Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease. Antioxid Redox Signal 25, 61–77.
106. Kerr F, Sofola-Adesakin O, Ivanov DK, Gatliff J, Gomez Perez-Nievas B, Bertrand HC, Martinez P, Callard R, Snoeren I, Cocheme HM et al. (2017) Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease. PLoS Genet 13, e1006593.
107. Stack C, Ho D, Wille E, Calingasan NY, Williams C, Liby K, Sporn M, Dumont M & Beal MF (2010) Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med 49, 147–158.
108. Bott LC, Badders NM, Chen KL, Harmison GG, Bautista E, Shih CC, Katsuno M, Sobue G, Taylor JP, Dantuma NP et al. (2016) A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy. Hum Mol Genet 25, 1979–1989.
109. Tian YP, Che FY, Su QP, Lu YC, You CP, Huang LM, Wang SG, Wang L & Yu JX (2017) Effects of mutant TDP-43 on the Nrf2/ARE pathway and protein expression of MafK and JDP2 in NSC-34 cells. Genet Mol Res 16, 1–13.
110. Moujalled D, Grubman A, Acevedo K, Yang S, Ke YD, Moujalled DM, Duncan C, Caragounis A, Perera ND, Turner BJ et al. (2017) TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. Hum Mol Genet 26, 1732–1746.
111. Sheng XJ, Tu HJ, Chien WL, Kang KH, Lu DH, Liou HH, Lee MJ & Fu WM (2017) Antagonism of proteasome inhibitor-induced heme oxygenase-1 expression by PINK1 mutation. PLoS One 12, e0183076.
112. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158–1160.
113. Jin YN, Yu YV, Gundemir S, Jo C, Cui M, Tieu K & Johnson GV (2013) Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. PLoS One 8, e57932.